UNSPSC 51152022: Cyclobenzaprine

This classification denotes a muscle relaxant with the molecular formula C20H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69O5WQQ5TI, chemically known as 10,11-dehydroamitriptyline but generally known as cyclobenzaprine, which bears US NIH Compound Identifier 2895. European Medicines Agency schedules Cyclobenzaprine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06849MIG.

UNSPSC 51152022 Cyclobenzaprine, a Commodity code, nominally covers a specific muscle-relaxant pharmaceutical product, but the recent state and local opportunities posted under this code show minimal alignment with the code's scope. The Seminole County, Florida IFB solicitation (IFB60459723LAS) requests Naloxone and Safe Drug Deactivation Systems for community health initiatives, while the Texas Health and Human Services Commission RFI (HHS0017013) explores vendor capabilities for a Direct-to-Manufacturer Prescriptions program under a Therapeutic Pharmacy Initiative—neither of which involves cyclobenzaprine procurement. State and local issuing bodies using this code include county health departments and state health agencies, though the recent opportunities reflect broader pharmaceutical procurement and pharmacy benefit management strategy rather than targeted muscle-relaxant commodity buying.

Geographic activity appears concentrated in Florida and Texas based on recent postings. Seminole County's naloxone procurement, posted June 30, 2026 with an IFB response deadline of July 26, 2023, targets annual delivery of 1,900 units of naloxone and 800 Safe Drug Deactivation Systems to the Seminole County Community Health Building in Sanford, with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas HHS Commission's RFI, posted April 3, 2026, functions as exploratory market intelligence rather than a competitive award opportunity and seeks vendor input on direct-to-manufacturer prescription contracting models without specifying budget, contract duration, or formal evaluation criteria. The code shows little relevant recent activity directly aligned to cyclobenzaprine procurement; the tagging appears to reflect broader pharmaceutical category assignment rather than specific muscle-relaxant commodity buying.